Statistical Methodological Research

Within biometrical and epidemiological research we aim to develop statistical methods that optimize planning and analysis of clinical and epidemiological studies.

Our statistical research focuses on:

  • Multistage Models
  • Adaptive Designs
  • Sample Size Calculation and Recalculation
  • Multiple Testing Problems

isTab: false


Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation?
Albert C, Haase M, Albert A, Zapf A, Braun-Dullaeus R, Haase-Fielitz A
ANN LAB MED. 2021;41(1):1-15.

A potential for seamless designs in diagnostic research could be identified
Vach W, Bibiza E, Gerke O, Bossuyt P, Friede T, Zapf A
J CLIN EPIDEMIOL. 2021;129:51-59.


Reevaluation of risk factors for time to subsequent events after first stroke occurrence using a new weighted all-cause effect measure
Ozga A, Rauch B, Palm F, Urbanek C, Grau A, Becher H, Rauch G
BMC PUBLIC HEALTH. 2020;20(1):817.

Sample size calculation and re-estimation based on the prevalence in a single-arm confirmatory diagnostic accuracy study
Stark M, Zapf A
STAT METHODS MED RES. 2020 [Epub ahead of print];1–14.

Blinded sample size reestimation for negative binomial regression with baseline adjustment
Zapf A, Asendorf T, Anten C, Mütze T, Friede T
STAT MED. 2020;39(14):1980-1998.

Why do you need a biostatistician?
Zapf A, Rauch G, Kieser M
BMC MED RES METHODOL. 2020;20(1):23.

Adaptive trial designs in diagnostic accuracy research
Zapf A, Stark M, Gerke O, Ehret C, Benda N, Bossuyt P, Deeks J, Reitsma J, Alonzo T, Friede T
STAT MED. 2020;39(5):591-601.


Introducing a new estimator and test for the weighted all-cause hazard ratio
Ozga A, Rauch G
BMC MED RES METHODOL. 2019;19(1):118.

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
Rossi A, Voigtländer M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M
J ONCOL. 2019;2019:8970645.

What makes a biostatistician?
Zapf A, Huebner M, Rauch G, Kieser M
STAT MED. 2019;38(4):695-701.


A systematic comparison of recurrent event models for application to composite endpoints
Ozga A, Kieser M, Rauch G
BMC MED RES METHODOL. 2018;18(1):2.

Appraising Heterogeneity
Zapf A
2018. Diagnostic Meta-Analysis . Biondi-Zoccai G (eds.). 1. ed. Berlin: Springer International Publishing, 125-160.


Investigation of the performance of trimmed estimators of life time distributions with censoring
Clarke B, Höller A, Müller C, Wamahiu K
AUST NZ J STAT. 2017;59(4):513-525.

Do we consent to rules of consent and confidentiality?
Wegscheider K, Friede T
BIOMETRICAL J. 2017;59(2):235-239.

Big Data Analytics
Wegscheider K, Koch-Gromus U
2017. Lehrbuch Versorgungsforschung Systematik - Methodik - Anwendung. Pfaff H, A.M. Neugebauer E, Glaeske G, Schrappe M (eds.). 2.. ed. Schattauer, 134-139.

Doppelgänger lehren uns das Grundprinzip des statistischen Testens
Zapf A, Frömke C, Rosenberger A
2017. Zeig mir mehr Biostatistik . Vonthein R, Burkholder I, Muche R, Rauch G (eds.). Berlin, Heidelberg: Springer Spektrum, Berlin, Heidelberg, 61-70.


Teilhabeforschung: Bedeutung, Konzepte, Zielsetzung und Methoden
Brütt A, Buschmann-Steinhage R, Kirschning S, Wegscheider K

Safety data from randomized controlled trials: applying models for recurrent events.
Hengelbrock J, Gillhaus J, Kloss S, Leverkus F
PHARM STAT. 2016;15(4):315-323.

Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard
Karch A, Koch A, Zapf A, Zerr I, Karch A
J CLIN EPIDEMIOL. 2016;78:73-82.

Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example
Winzer K, Buchholz A, Schumacher M, Sauerbrei W
PLOS ONE. 2016;11(3):e0149977.

Measuring inter-rater reliability for nominal data - which coefficients and confidence intervals are appropriate?
Zapf A, Castell S, Morawietz L, Karch A

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
zu Eulenburg C, Suling A, Neuser P, Reuss A, Canzler U, Fehm T, Luyten A, Hellriegel M, Woelber L, Mahner S
PLOS ONE. 2016;11(11):e0165705.


Simulating recurrent event data with hazard functions defined on a total time scale
Jahn-Eimermacher A, Ingel K, Ozga A, Preussler S, Binder H

Nutzenbewertung aus Sicht der Versorgungsforschung und der Epidemiologie.
Wegscheider K, Drabik A, Bleich C, Schulz H

Die Versorgungsforschung als möglicher Profiteur von Big Data
Wegscheider K, Koch-Gromus U

A wild bootstrap approach for the selection of biomarkers in early diagnostic trials
Zapf A, Brunner E, Konietschke F

Nonparametric meta-analysis for diagnostic accuracy studies
Zapf A, Hoyer A, Kramer K, Kuss O
STAT MED. 2015;34(29):3831-3841.


A measure for assessing functions of time-varying effects in survival analysis
Buchholz A, Sauerbrei W, Royston P
Open J Stat. 2014;4(11):977-998.

A modified Wald interval for the area under the ROC curve (AUC) in diagnostic case-control studies
Kottas M, Kuss O, Zapf A

Disease-Management-Programme - was wurde bisher erreicht?
Wegscheider K, Drabik A, Kaduszkiewicz H, Schäfer I, Bussche van den H
2014. Ergebnisverbesserung durch Qualitätsmanagement - Aktuelle Maßnahmen, Nachweise, Stand der Evaluierung. Jonitz G, Mansky T, Scriba P, Selbmann H (eds.). 1. ed. Köln: Deutscher Ärzte-Verlag, 145-154.


Difference of two dependent sensitivities and specificities: Comparison of various approaches
Wenzel D, Zapf A
BIOMETRICAL J. 2013;55(5):705-718.

Letzte Aktualisierung aus dem FIS: 12.05.2021 - 07:03 Uhr